Transient receptor potential melastatin 7 (TRPM7), a non-selective cation channel, is highly expressed expressed in the brain and plays a critical role in ischemic neuronal death. Astrocyte, the most abundant cell type in central nervous system (CNS), exerts many essential functions in the physiological and pathological conditions. Here we investigated the expression and functions of the TRPM7 channel in mouse cortical astrocytes. Using reverse transcription (RT)-PCR, immunostaining, western blot and patch clamp recording, we showed that functional TRPM7 channel is expressed in cultured mouse cortical astrocytes. Knocking down TRPM7 with specific siRNA impairs the proliferation and migration of astrocytes by 40.2% ± 3.9% and 40.1% ± 11.5%, respectively. Consistently, inhibition of TRPM7 with 2-aminoethoxydiphenyl borate (2-APB) also decreases astrocyte proliferation and migration by 46.1% ± 2.5% and 64.2% ± 2.4%. MAPKs and Akt signaling pathways have been shown to be implicated in TRPM7-mediated responses including cell proliferation and migration. Our data show that suppression of TRPM7 in astrocytes reduces the phosphorylation of extracellular signal-regulated kinases (ERK) and c-Jun N-terminal kinases (JNK), but not p38 mitogen-activated protein kinase and Akt. In addition, TRPM7, as a cation channel, has been involved in the Ca2+ and Mg2+ homeostasis in several types of cells. In our study, we found that silencing TRPM7 decreases the intracellular basal Mg2+ concentration without affecting Ca2+ concentration in astrocytes. However, an addition of Mg2+ to the growth medium could not rescue the impaired proliferation of astrocytes. Together, our data suggest that TRPM7 channel may play a critical role in the proliferation and migration of astrocytes via the ERK and JNK pathways.
Citation: Zeng Z, Leng T, Feng X, Sun H, Inoue K, Zhu L, et al. (2015) Silencing TRPM7 in Mouse Cortical Astrocytes Impairs Cell Proliferation and Migration via ERK and JNK Signaling Pathways. PLoS ONE 10(3): e0119912. https://doi.org/10.1371/journal.pone.0119912
Academic Editor: Ken Arai, Massachusetts General Hospital/Harvard Medical School, UNITED STATES
Received: July 23, 2014; Accepted: January 17, 2015; Published: March 23, 2015
Copyright: © 2015 Zeng et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Data Availability: All relevant data are within the paper and its Supporting Information files.
Funding: This work was supported by National Institutes Health [grant R01NS047506 and R01NS066027 to Z.G.X.]; Minority Health and Health Disparities [grant S21MD000101 and U54NS083932]; American Heart Association [grant 0840132N to Z.G.X.]; Alzheimer's Association [grant IIRG-10-173350 to Z.G.X.]; Jiangsu Province’s Key Discipline of Medicine [grant XK201118 to L.Z.], and the Priority Academic Program Development of Jiangsu Higher Education Institutions of China [to L.Z.]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Astrocytes are specialized glial cells that outnumber neurons by over five folds in CNS. They play a variety of roles such as regulating the release of neurotrophic factors, modulating neuronal development and functions, metabolizing neurotransmitters, and regulating extracellular ion level and immune response [1–3]. Astrocytes can be activated and proliferated in response to some pathophysiological factors. These processes are called reactive astrogliosis. Reactive astrogliosis has become a pathological hallmark of CNS structural lesions and a therapeutic target for neurodegenerative diseases. Based on the dysfunction of astrocytes in some pathologic status, the strategy to restore or enhance astrocyte functions could be an appealing way to promote brain functions . Transient receptor potential (TRP) ion channels play an important role in diverse cellular processes in the CNS. Astrocytes express several TRP channels including TRPA1, TRPC1, TRPC3, TRPC4, TRPC5, TRPV2 and TRPV4. They play crucial roles in the regulation of astrocytic functions [5–9]. For example, TRPA1 was reported to regulate astrocyte intracellular Ca2+ concentration and inhibitory synaptic transmission [9, 10]. TRPV4 is involved in ischemia-mediated increases of intracellular Ca2+ in astrocytes . TRPC3 mediates thrombin-induced astrocyte activity and upregulates its own expression . However, the expression and function of TRPM7 in astrocytes has not been elucidated.
TRPM7 is a member of the melastatin-related subfamily of TRP channels [12, 13]. It is a ubiquitously expressed channel protein that conducts diverse cations including Ca2+ and Mg2+, and possesses an alpha kinase domain in its C-terminal [13–16]. Increasing evidences show that TRPM7 channel plays an important role in fundamental cellular processes including survival, proliferation, cell cycle progression, magnesium homeostasis, and responses to shear stress and oxidative stress [15–17]. Previous studies indicated that TRPM7 is highly expressed in the brain and plays a critical role in anoxic neuronal death by mediating Ca2+ influx during the cerebral ischemia and prolonged oxygen-glucose deprivation (OGD) [18–21]. Suppression of TRPM7 in hippocampus CA1 neurons facilitates neuron survival after brain ischemia, and preserves neuronal morphology and function . Thus, TRPM7 has been considered as a potential target for treatment of ischemia brain injury . In addition, TRPM7 is also involved in several neurodegenerative diseases such as western pacific amyotrophic lateral sclerosis (ALS), parkinsonism dementia (PD), and Alzheimer’s disease (AD) [23, 24]. However, the studies on the role of TRPM7 in glial cells are still rare. Jiang et al. first identified TRPM7 transcripts and TRPM7-like current in rat microglia . Recently, Siddiqui et al found that TRPM7 enhances the migration and invasion of microglia in anti-inflammatory states . However, the physiological functions of TRPM7 in astrocytes are largely unknown. The present study demonstrates that the functional TRPM7 channel exists in mouse cortical astrocytes. Knocking down or inhibiting TRPM7 impairs the proliferation and migration of astrocytes. Previous studies showed that TRPM7 regulates cell proliferation and migration through several signaling pathways including MAPK and PI3K/AKT pathways [27–29]. The current study demonstrated that knocking down or inhibiting TRPM7 impairs the proliferation and migration of astrocytes via the ERK and JNK, but not p38 and Akt signaling pathways. In addition, TRPM7 channel, as a cation channel, is likely involved in the regulation of intracellular Mg2+ concentration of astrocytes.
Materials and Methods
Reagents and antibodies
2-APB, propidium iodide (PI) and protease inhibitors cocktail were purchased from Sigma (St. Louis, MO). Lactate dehydrogenase (LDH) assay kit and phosphatase inhibitors cocktail were from Roche (Indianapolis, IN). Fluo-3/acetoxymethyl ester (Fluo-3/AM) was purchased from Beyotime Institute of Biotechnology (Jiangsu, China). Mouse monoclonal anti-TRPM7 antibody (Cat# ab85016) and rabbit polyclonal anti-β-actin antibody (Cat# ab8227) were purchased from Abcam (Cambridge, MA). Rabbit polyclonal antibodies against phosphorylated-Akt (p-Akt, Ser473, cat# 4060), p-Akt (Thr308, Cat# 13038), p-ERK1/2 (Thr202/Tyr204, cat# 9101), p-JNK (Thr183/Tyr185 cat# 9251), total-Akt (t-Akt, cat# 9272), t-ERK1/2 (Cat# 9102), t-JNK (Cat# 9258), mouse monoclonal antibody against glial fibrillary acidic protein (GFAP, cat# 3670) and U0126 were purchased from Cell Signaling (Beverly, MA).
All animal experiments were approved by the Institutional Animal Care and Use Committee of Morehouse School of Medicine. Primary cortical astrocytes were isolated and cultured as described in a previous study with a few modification . Briefly, mouse cerebral cortices were isolated from about E18 embryos and digested with 0.25% trypsin-EDTA for 10 min at 37°C. The cells were dissociated by gentle pipetting with glass pipette and cultured in T75 flask with dulbecco's modified eagle medium (DMEM) plus 10% FBS, 40 U/mL penicillin and 100 μg/mL streptomycin. Neurons, oligodendrocytes, and microglial cells were removed by shaking the flask at 180 RPM for 16–18h and washing with PBS twice. The purity of astrocytes was verified by staining with GFAP antibody. Cultures with > 95% GFAP positive cells were used for the experiments.
Human embryonic kidney (HEK293) cell line with inducible expression of human TRPM7 channels (HEK/M7) was a gift from Dr. A. Scharenberg (University of Washington). Cells were cultured in minimal essential medium (MEM) complemented with 10% FBS and antibiotics . TRPM7 expression was induced by the addition of 1 μg/mL tetracycline.
Knockdown of TRPM7 experiments were performed as described previously . Briefly, siRNA against TRPM7 corresponding to coding region 5152–5172 (TRPM7 siRNA-1, Genebank# AY032951)  and 1630–1650 (TRPM7 siRNA-2, Genebank# NM_021450)  were synthesized by Invitrogen. Cells were transfected with 50 nM siRNA using transfection reagent lipofectamine RNAiMAX or lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions. Non-targeting siRNA (Invitrogen, Carlsbad, CA) was used as a control siRNA.
RT-PCR and quantitative RT-PCR
RT-PCR was performed as described previously . Briefly, total RNAs of astrocytes were extracted with RNA purification kit (Qiagen, Valencia, CA) and transcribed to cDNA using superscript First-strand synthesis system (Invitrogen, Carlsbad, CA). Quantitative RT-PCR was performed using SYBR Green supermix (Bio-rad, Richmond, CA) in C1000 Thermal cycler (Bio-rad) as described. The primer sequences were described in the “Table 1”.
Whole-cell voltage-clamp recordings were performed as described previously . Patch electrodes were constructed from thin-walled borosilicate glass (WPI) and had resistances of 1 to 3 MΩ. Currents were recorded using Axopatch 200B amplifier with pCLAMP software (Axon Instruments). They were filtered at 2 kHz and digitized at 5 kHz using Digidata 1322A. Data were eliminated from statistical analysis when access resistance was >10 MΩ or leak current was >100 pA at −60 mV. A multibarrel perfusion system was used to achieve a rapid exchange of external solutions. Standard extracellular solution contained (in millimolar) 140 NaCl, 5.4 KCl, 2 CaCl2, 1 MgCl2, 20 HEPES, 10 glucose (pH 7.4 adjusted with NaOH; 320–335 mOsm). Patch electrodes contained (in millimolar) 140 CsF, 10 HEPES, 1 CaCl2, 11 EGTA, 2 TEA, (pH 7.25 adjusted with CsOH, 290–300 mOsm). In order to potentiate the TRPM7-like current, the extracellular CaCl2 and MgCl2 were removed. For investigating the current–voltage (I–V) relationship, a voltage ramp between −100 mV and +100 mV from a holding potential of −60 mV was applied as described previously . All experiments were done at the room temperature.
Cell proliferation assay
Total LDH assay has been used to assess the cell proliferation as previously described [28, 34]. Cells were plated in 24-well plate at a density of 2–3 × 104 cells/well. After starved for 24h in serum free DMEM, cells were transfected with siRNA or treated with indicated drugs for 3–4 days. Cells were washed twice with PBS and lysed with 1% Triton X-100 in PBS. Supernatant was taken for LDH assay according the manufacturer’s protocol of kit (Roche Diagnostics). The absorbance was examined by spectrometer (SpectraMax Plus, Molecular devices).
Cells were starved with serum-free medium for 24h and the cell monolayer was scratched with a 1000 μl pipette tip. After washed 3 times with serum-free medium, the images of original wound area were taken with microscope (Olympus FSX100, 4.2×). Cells were incubated with DMEM containing 1% FBS for 3 days at 37°C. 3 days later, images were taken from the same location of wound area with the same microscope and analyzed using NIH Image J software. Migration rate was calculated as: % wound closure = [(Area of original wound—Area of wound after healing)/Area of original wound] × 100%.
Cells growing on coverslip pre-coated with Poly L-ornithine were washed twice with PBS and then fixed with 4% paraformaldehyde for 30 min. The cells were permeabilized with 0.2% Triton X-100 in PBS for 10 min and blocked with 3% BSA in PBS for 60 min. After incubated with primary antibody against TRPM7 (1:100) and GFAP (1:250) at 4°C overnight. The coverslips were washed three times at a 5 min interval and then incubated with FITC-conjugated goat anti-mouse secondary antibody for 1h at room temperature, mounted with DAPI solution followed by observing under fluorescence microscope.
Western blotting was performed as described previously . Briefly, cells were first lysed in RIPA buffer (50 mM Tris-HCL, pH 7.4, 150 mM NaCl, 1% Triton X-100, 0.5% Sodium deoxycholate, 0.1% SDS, protease inhibitor and phosphatase inhibitor cocktail). After centrifugation at 13,000g at 4°C for 10 min, the supernatant was collected. The aliquots were mixed with laemmli sample buffer and boiled at 95°C for 10 min. Proteins were separated by 10% SDS-PAGE, transfered to PVDF membranes, and then incubated with different primary antibodies against TRPM7 (1:200), β-actin (1:2000), p-p38 (1:1000), p-ERK1/2 (1:1000), p-JNK (1:500), p-Akt (Ser473, 1:1000), p-Akt (Thr308, 1:1000), t-p38 (1:500), t-ERK1/2 (1:1000), and t-JNK (1:500). Membranes were incubated with HRP or IRDye 800-conjugated secondary antibodies (1:2000) for 1h at room temperature. The signals were visualized with ECL kit or LI-COR Odyssey. The intensity of the protein band was quantified with Image J software (NIH).
Mg2+ and Ca2+ assay
Intracellular Mg2+ concentration was quantified by QuantiChrom Magnesium Assay Kit (BioAssay Systems) according to the manufacturer’s instruction. Briefly, cells were washed 3 times with Ca2+ and Mg2+ -free PBS and collected in 100ul Ca2+ and Mg2+ -free PBS with a scraper. Suspension (10 μl) was taken for protein assay using BCA assay kit (Pierce). The remaining suspension was incubated with 5% (w/v) trichloroacetic acid at room temperature for 5 min. The supernatant was harvested by centrifuge at 14,000 rpm for 2 min, and some aliquots were taken for Mg2+ concentration assay according to the kit instruction. While intracellular Ca2+ levels were determined with the Ca2+-sensitive fluorochrome Fluo-3/acetoxymethyl ester (Fluo-3/AM) by a Becton Dickinson FACS Calibur flow cytometer as described in a previous study . Briefly, cells were suspend in Tyrode’s buffer (134 mM NaCl, 12 mM NaHCO3, 2.9 mM KCl, 0.34 mM Na2HPO4, 1 mM MgCl2, 1mM CaCl2, 10 mM Hepes, pH 7.4), and incubated with 5 μM Fluo-3/AM at room temperature for 30 min in the dark. Extracellular free dye was washed away with Tyrode’s buffer. The fluorescence of Fluo-3 in cells was analyzed by flow cytometry (BD Bioscience).
Expression of TRPM7 in cortical astrocytes
Cortical astrocytes were isolated from mouse cerebral cortex and purified as described in previous study . Glial fibrillary acidic protein (GFAP, a marker of astrocytes) staining suggested that >95% of cells were astrocytes (S1 Fig.). Total RNAs were extracted from cortical astrocytes and reverse transcribed to cDNA. RT-PCR results showed a clear band of expected size in the astrocytes panel, but no band in the no-template control panel (Fig. 1A). Next, we examined the presence of TRPM7 protein by immunocytochemistry. As shown in Fig. 1B, tetracycline (Tet) drastically increased TRPM7 expression (green) in HEK293 cells with inducible expression of TRPM7 (HEK/M7) compared to cells not treated with tetracycline (Fig. 1B, upper row). Astrocytes showed a clear fluorescence signal when using the same antibody against TRPM7 under the same condition (Fig. 1B, under row). As shown in Fig. 1C, TRPM7 channels are located in whole cell body of astrocytes, and enriched in plasma membranes and nucleus (Fig. 1C). Taken together, these results indicate that TRPM7 channel is expressed in cultured mouse cortical astrocytes.
A. Reverse transcript (RT)-PCR shows a clear band with the expected size exists in cortical astrocytes (left panel) but no band in no template control (right panel). B. Immunostaining shows that tetracycline (Tet) drastically increases TRPM7 expression (green) in TRPM7-expressing HEK293 cells (HEK/M7) compared to cells not treated with tetracycline (upper row). Cells are stained with DAPI (blue) to reveal the nuclei. Scale bar, 50 μm. C. Representative images show the localization of TRPM7 in astrocytes. Arrows indicate the cell membrane. Scale bar, 50 μm.
Knockdown of TRPM7 in cortical astrocytes
In order to further investigate the expression and role of TRPM7 in mouse cortical astrocytes, we synthesized two pairs of specific siRNAs against mouse TRPM7 as described in previous studies (see methods). As shown in Fig. 2A, TRPM7 siRNA-1 and siRNA-2 decreased the expression of TRPM7 mRNA by 71.6% ± 11.9% and 70.2% ± 8.9% respectively compared to the control siRNA (Fig. 2A and 2B). However, they had no effect on the mRNA expression of TRPM4 and TRPM6 (homologous genes for TRPM7). Consistently, western blotting analysis showed that TRPM7 siRNA-1 and siRNA-2 reduced the expression of TRPM7 protein by 50.9% ± 11.7% and 36.4% ± 6.1% respectively (Fig. 2C and 2D). In addition, quantitative RT-PCR demonstrated that the mRNA of TRPM7 in astrocytes was decreased to 34.9% ± 2.7% by TRPM7 siRNA-1 (Fig. 2E). We selected the TRPM7 siRNA-1 for the rest of study because of its higher efficiency.
A. RT-PCR shows that transfection of astrocytes with specific TRPM7 siRNA decreases the mRNA level of TRPM7 compared to those with control siRNA. However, the mRNA levels of homologous genes TRPM4 and TRPM6 were not changed. B. Quantification of the expression of TRPM7, TRPM4 and TRPM6 mRNA in astrocytes treated with control siRNA or TRPM7 siRNA. Normalized TRPM7 mRNA expression shows a significant decrease after transfection with TRPM7 siRNA-1 (by 71.6% ± 11.9%) and siRNA-2 (by 70.2% ± 8.9%) as compared to control siRNA (*, p<0.05, n = 3). TRPM4 and TRPM6 mRNA levels were not changed (n = 3). C. Western blotting shows that TRPM7 siRNA-1 and siRNA-2 decrease the protein level of TRPM7 in astrocytes as compared to control siRNA. D. Quantification of TRPM7 protein level in astrocytes transfected with control siRNA and TRPM7 siRNAs. TRPM7 siRNA-1 significantly decreases TRPM7 protein expression by 50.9% ± 11.7%, while TRPM7 siRNA-2 decreases TRPM7 protein by 36.4% ± 6.1% (*, p < 0.05, n = 3). E. Quantitative RT-PCR confirms the reduction of TRPM7 mRNA normalized to β-actin in astrocytes transfected with TRPM7 siRNA-1 compared to those with control siRNA (*, p < 0.05, n = 3).
TRPM7-like currents in cultured astrocytes
Next, we investigated the existence of functional TRPM7 channels in cultured astrocytes by whole-cell patch-clamp recording. As expected, removal of extracellular Ca2+ and Mg2+ potentiated the TRPM7-like inward currents in cortical astrocytes (n = 8, Fig. 3A and 3B). TRPM7 channels exhibit slightly outwardly-rectifying I-V relationship in the absence of divalent cations (Fig. 3B). Silencing TRPM7 with siRNA significantly decreased the current density by 67.9% (from −3.18 ± 0.88 pA/pF to −1.02 ± 0.23 pA/pF) (Fig. 3C and 3D), further confirming the expression of functional TRPM7 channels in cortical astrocytes.
A. Voltage ramp (-100 to +100 mV) was applied for 4s from a holding potential of −60 mV. TRPM7 currents were potentiated in the absence of Ca2+ and Mg2+. B. Current-voltage relationship (I-V curve) was derived from A. n = 8. C. Representative traces showing the I-V curve of TRPM7 channels in astrocytes treated with control-siRNA or TRPM7-siRNA in the absence of Ca2+ and Mg2+. D. Removal of extracellular Ca2+ and Mg2+ potentiates the whole-cell TRPM7-like inward current at the −60 mV. Knockdown of TRPM7 reduces the peak current in astrocytes when transfected with TRPM7 siRNA. Quantification of current density shows that transfection of astrocytes with TRPM7 siRNA-1 (n = 10) significantly decreases the current density by 67.9% compared to control siRNA (n = 13, *, p < 0.05).
Effect of TRPM7 on the growth/proliferation of cortical astrocytes
TRPM7 has been reported to affect the survival and proliferation of various cell types . We first determined whether TRPM7 also influence astrocyte proliferation. As shown in Fig. 4A, the cell density of cortical astrocytes in culture wells transfected with TRPM7 siRNAs appears to be lower than those transfected with control siRNA (Fig. 4A). In order to quantify the change of cell number, we assayed total LDH value because the total amount of LDH is proportional to the total number of cells available in the culture [28, 34] (S2 Fig.). As shown in Fig. 4B, both TRPM7 siRNA-1 and siRNA-2 significantly inhibited the growth/proliferation of cortical astrocytes by 40.2% ± 3.9% and 15.9% ± 3.5% respectively (Fig. 4B). Similar to TRPM7 knockdown, a non-selective TRPM7 inhibitor 2-APB also inhibited the proliferation of cortical astrocytes by 46.1% ± 2.5% (Fig. 4C). In contrast, treatment of cells with vehicle DMSO had no effect compared to the non-treated cells (Fig. 4C). Since TRPM7 siRNA-1 seemed to be more effective than TRPM7 siRNA-2 in knocking down TRPM7 (Fig. 2) and astrocyte proliferation (Fig. 4B), we focused on TRPM7 siRNA-1 for the following experiments.
A. Representative images show the proliferation of astrocytes treated with control siRNA or TRPM7 siRNA. Scale bar: 50 μm. B. Quantification of the proliferation of astrocytes with different treatments. Transfection of astrocytes with TRPM7 siRNA-1 significantly reduces the proliferation by 40.2% ± 3.9% (n = 5; *, p < 0.05), while transfection of astrocytes with TRPM7 siRNA-2 reduces the proliferation by 15.9% ± 3.5% (n = 3) compared to control siRNA. Control siRNA has no effect on astrocyte proliferation compared to untreated control. C. TRPM7 inhibitor 2-APB (100 μM, n = 4) significantly decreases the proliferation of cortical astrocytes by 46.1% ± 2.5% (*, p < 0.05).
Effect of TRPM7 on cortical astrocyte migration
Astrocyte migration exerts a complex function in CNS lesion. Astrocytes could rapidly proliferate and migrate to the location of damage in response to brain injury [36, 37]. Thus, we next investigated the role of TRPM7 on astrocyte migration using the scratch wound healing model. Fig. 5A showed typical images of wound healing assay performed on HUVECs. Quantification analysis of these images showed that knocking down TRPM7 significantly inhibited astrocyte migration by 40.1% ± 11.5% compared to control siRNA (Control vs. TRPM7 siRNA-1: 63.5% ± 2.6% vs. 38.1% ± 23.0%, Fig. 5B). Consistently, 2-APB also inhibited astrocyte migration by 64.2% ± 2.4% compared to DMSO control (DMSO vs. 2-APB: 57.2% ± 4.5% vs. 20.4% ± 1.4%, Fig. 5C and 5D).
A and C. Representative images show wound healing closure of cortical astrocytes with different treatment after scratch injury from 0 day to 3 days. B and D. Quantification of wound healing closure of astrocytes. Silencing TRPM7 decreases the migration rate by 40.1 ± 11.5% (from 63.5% to 38.1%; **, p<0.01; n = 6) Inhibition of TRPM7 with 2-APB (100 μM) drastically impairs astrocyte migration by 64.2 ± 2.4% (from 57.2 ± 4.5% vs. 20.4 ± 1.4%; ***, p < 0.001; n = 6).
Potential mechanisms underlying the effect of TRPM7-silencing on astrocyte proliferation and migration
MAPK and PI3K/Akt signaling pathways are involved in diverse cellular physiological processes including growth and proliferation. TRPM7 has been implicated in regulating MAPK and PI3K/Akt signaling in several cell types [27–29]. For these reasons, we investigated whether MAPK and PI3K/Akt signaling pathways are involved in TRPM7–mediated astrocyte proliferation and migration. To determine the activity of MAPKs and PI3K, we detected the phosphorylated form of ERK1/2, JNK, p38 and Akt using phospho-specific antibodies. Western blotting results showed that the phosphorylation of ERK and JNK in TRPM7-silent astrocytes clearly decreased as compared to control siRNA treated cells (Fig. 6A). Densitometric analysis of bands showed that p-ERK and p-JNK are reduced by 67.8% ± 22.4% and 80.5% ± 25.3% respectively (Fig. 6B). However, there are no significant changes of phosphorylation of p38 and Akt (Ser473 and Thr308) (Fig. 6A and 6B). Consistently, 2-APB inhibits the phosphorylation of ERK and JNK by 75.6% ± 43.9% and 88.9% ± 19.1% respectively (Fig. 6C and 6D). Furthermore, treatment of cortical astrocytes with U0126 (10 μM, MEK1/2 inhibitor) or SP600125 (20 μM, JNK inhibitor) inhibited cell proliferation by 36.3% ± 11.8% and 42.9% ± 7.8% respectively (Fig. 7A and 7B), and wound healing by 17.9% ± 3.7% and 60% ± 4.1% respectively (Fig. 7C and 7D). These results suggested that Silencing TRPM7 inhibited the proliferation and migration of cortical astrocytes likely through the reduced activity of ERK and JNK.
A. Western blot shows that TRPM7 siRNA decreases the expression of TRPM7 protein, phosphorylated ERK and JNK, but has no effect on phosphorylated p38 and Akt, as compared to the control siRNA. B. Densitometric analysis shows a decrease of p-ERK and p-JNK. TRPM7 siRNA significantly decreases the protein level of TRPM7 by 36.5% (n = 3), the phosphorylation of ERK and JNK by 67.8% ± 22.4% (n = 3) and 80.5% ± 25.3% (n = 3) respectively (*, p < 0.05). C and D. 2-APB significantly inhibits the phosphorylation of ERK and JNK by 75.6% ± 43.9% (n = 3) and 88.9% ± 19.1% (n = 4) respectively as compared to the DMSO control (*, p < 0.05).
A and B. MEK inhibitor (U0126, 10 μM) and JNK inhibitor (sp600125, 20 μM) inhibit astrocyte proliferation by 36.3% ± 11.8% and 42.9% ± 7.8% respectively (*, p < 0.05, n = 4). C and D. MEK inhibitor (U0126, 10 μM) and JNK inhibitor (sp600125, 20 μM) inhibit astrocyte migration by 17.9% ± 3.7% and 60.0% ± 4.1% respectively (*, p < 0.05; **, p < 0.01, n = 6).
Effect of TRPM7 on intracellular Mg2+ and Ca2+ concentration in astrocytes
As a cation-permeable channel, TRPM7 was implicated in the regulation of Ca2+ and Mg2+ homeostasis in several kinds of cells [18, 38]. We next determined whether knocking down TRPM7 affected intracellular Mg2+ and Ca2+ concentration in cortical astrocytes. As shown in Fig. 8A, overexpressing TRPM7 in HEK293 cells dramatically increased intracellular Mg2+ by 73.7% ± 7.2%. In cortical astrocytes, knocking down TRPM7 significantly reduced the intracellular basal Mg2+ by 43.5% ± 9.8% (Fig. 8A). Flow cytometry analysis showed that most astrocytes loaded with Fluo-3 AM dye have a strong positive signal compared to negative control which did not load any dye (Fig. 8B). However, silencing TRPM7 did not change the basal level of intracellular Ca2+ in cortical astrocytes (Fig. 8C).
A. Overexpression of TRPM7 in HEK/M7 cells induced by 1 μg/mL tetracycline drastically increases intracellular Mg2+ concentration by 73.7% ±7.23% (*, p < 0.05, n = 3). However, knockdown of TRPM7 in mouse cortical astrocytes significantly decreases intracellular Mg2+ by 43.5% ± 9.8% (*, p < 0.05, n = 4). B. Intracellular Ca2+ concentration of cortical astrocytes is analyzed by flow cytometry. All astrocytes loaded with Fluo-3 AM have a strong fluorescence signal compared to the negative control which has not been loaded with any dye. C. Quantification of intracellular Ca2+ concentration indicates significant difference between control siRNA and TRPM7 siRNA treatments (n = 5). D. increasing extracellular Ca2+ and Mg2+ has no effect on the proliferation of cortical astrocytes. Addition of Ca2+ and Mg2+ to growth medium has no effect on the proliferation of cortical astrocytes, and could not rescue the inhibition of astrocyte proliferation induced by silence of TRPM7 (*, p < 0.05, n = 4).
Effect of extracellular Mg2+ and Ca2+ on the proliferation of astrocytes
Addition of extracellular cations has been shown to rescue the defect induced by TRPM7 silencing in several kinds of cells . Using the proliferation assay, we determined whether extracellular Ca2+ and Mg2+ will rescue the defect of astrocytes transfected with TRPM7 siRNA. As shown in Fig. 8D, an addition of 5 mM—10 mM Mg2+ or 10 mM Ca2+ to the medium already contained 0.8 mM Mg2+ and 1.8 mM Ca2+ did not affect the growth/proliferation of astrocytes (Fig. 8D, left 4 white columns). Similarly, an addition of Mg2+ or Ca2+ also did not rescue the inhibited proliferation of TRPM7-silent astrocytes (Fig. 8D, right 4 black columns). These findings indicated that TRPM7 mediated astrocyte proliferation might be independent on the Ca2+ and Mg2+ influx. Alternatively, TRPM7 might not be the only pathway for Mg2+ entry in astrocytes. As was shown by Su et al., expression of a Mg2+ transporter could rescue the defects caused by knockdown of TRPM7 .
Astrocytes are specialized glial cells responsible for a wide variety of complex and essential functions in CNS, and play important roles in the regulation of disease processes. Several TRP channels have been reported to express in astrocytes and play crucial roles in astrocyte functions. Here we showed that functional TRPM7 channel was expressed in murine primary astrocytes. In addition, we showed that TRPM7 channel regulated astrocyte proliferation and migration through the ERK and JNK signaling pathways. As a Ca2+ and Mg2+-permeable channel, TRPM7 was found to regulate intracellular Mg2+ concentration of astrocytes. Together, our data reveal a new role for TRPM7 channel in the regulation of the physiological function of astrocytes in vitro.
TRPM7 is ubiquitously and highly expressed in brain and plays an important role in the pathophysiology of CNS like ischemic stroke [20, 21]. Most previous studies concentrated on the functions of TRPM7 channel in neurons under different pathophysiological status such as ischemic stroke, oxygen-glucose deprivation (OGD), oxidative stress, hypoxia and inflammation [18, 40]. In this study, we investigated the expression and function of TRPM7 in astrocyte, a specialized glia cell that outnumber neurons by over five fold. It is not surprising that functional TRPM7 channels were expressed in primary cultured cortical astrocytes, as is shown in other cells . However, it is important that TRPM7 channel promotes astrocyte proliferation and migration via the ERK and JNK signaling pathways. TRPM7 channel plays a critical role in diverse cellular processes including proliferation, migration, adhesion, differentiation, and apoptosis. It is intriguing that TRPM7 channel performs different functions in different cells. TRPM7 promotes the proliferation, migration or differentiation in several types of cells such as macrophage , hepatic stellate cells , human prostate cells , human lung fibroblast , and pre-adipocytes . In contrast, TRPM7 channel plays a negative function in human umbilical endothelial cells (HUVECs) including inhibition of proliferation and migration and enhancement of hyperglycemia-induced injury [28, 46, 47]. One possible reason for the different effects of TRPM7 is that there are significant differences in basal gene expression profiles and intracellular signaling machinery in different cells. Another possible reason may refer to the activity of TRPM7 itself because channel and kinase domain of TRPM7 can perform their functions independently. In addition, the substrates of TRPM7 kinase such as calpain, myosin heavy chain and annexin I might also be involved in these processes, which may result in different reaction [48–50]. Given that astrocytes exerts many essential complex functions in healthy CNS (see review ), TRPM7 channels may be a new potential regulator for astrocyte-related CNS physiological functions.
TRPM7 channel mediates several signaling pathways including MAPK and PI3K pathways which play important roles in cell proliferation and migration. For example, TRPM7 channel regulates PDGF-BB-induced proliferation of hepatic stellate cells via PI3K and ERK pathways . Silencing TRPM7 promotes HUVEC proliferation by activating the ERK pathway . TRPM7 mediates DT40 cell growth through the PI3K/Akt signaling pathway . Notably, TRPM7 regulates cell proliferation or migration through different signaling pathways in different cells. In cortical astrocytes, knockdown of TRPM7 selectively impairs the activity of ERK and JNK, but has no effect on p38 and Akt. Furthermore, a variety of previous studies have also demonstrated that ERK and JNK played a crucial role in physiological functions of astrocytes including proliferation and migration [52, 53]. ERK was involved in both basal and stimulated astrocyte proliferation, while selective inhibitors such as PD98059 and U0126 led to the inhibition of astrocyte proliferation . Similarly, JNK pathway was involved in astrocyte growth and proliferation as well. It has been shown that angiotensin II and III regulate astrocyte proliferation by activating JNK signaling [53, 54]. However, it does not exclude the possibility that other signal pathways like JAK/STAT pathway might also be involved in TRPM7-mediated astrocyte proliferation, just as TRPM7 channel regulates glioma stem cells through STAT3 and Notch signaling pathways . Other ways might also be available because TRPM7 possesses both channel and kinase domain. In some case, silencing TRPM7 mimics the deficiency of magnesium by inhibiting cell proliferation and migration [38, 56]. In addition, the substrates of TRPM7 kinase like calpain, myosin heavy chain and annexin I might be involved in these processes as well . However, we cannot exclude other potential factors which may also be involved in TRPM7-mediated astrocyte proliferation and migration. Additional experiments using gene chip microarray or proteomics to compare the TRPM7-silent and WT astrocytes may be helpful for investigating the detailed mechanisms.
As a Ca2+ and Mg2+-permeable channel, TRPM7 regulates intracellular Ca2+ and Mg2+ homeostasis in most cells. However, it does not mean that altering TRPM7 expression or activity could always produce a change in intracellular Ca2+ or Mg2+ concentration. For example, overexpression of TRPM7 in HEK293 cells does not cause Ca2+ overload , but increases Mg2+ concentration (Fig. 8A). Deletion of TRPM7 disrupts embryonic development and thymopoiesis without altering Mg2+ homeostasis . In addition, Akita et al demonstrated that TRPM7 was not involved in bradykinin–induced Ca2+ influx in astrocytes . Similarly, we found that silencing TRPM7 in astrocytes does not alter the concentration of intracellular Ca2+, but decreases the concentration of Mg2+. However, the exact mechanism by which TRPM7 selectively conducts Ca2+ or Mg2+ is unknown in these cells. Interestingly, Mg2+ plays an important role in the physiological functions of CNS . Lowering the intracellular Mg2+, for example, is expected to compromise the integrity of blood-brain barrier (BBB) . Magnesium has also been shown to prevent the loss of synapse and reverse cognitive deficits in Alzheimer’s disease . In addition, Mg2+ can decrease brain edema formation after traumatic brain injury (TBI) by restoring the polarized state of astrocytes and by down-regulation of AQP4 channels in astrocytes . It suggests that TRPM7-mediated change in Mg2+ concentration may play an important role in the pathophysiological processes of CNS. However, its exact roles still need further investigation. In some case, supplement of extracellular Mg2+ in growth medium could rescue the proliferative defect induced by TRPM7 deficiency [38, 62]. However, this did not occur in astrocytes in the present study (Fig. 8D). One possible reason is that astrocyte proliferation induced by TRPM7 silencing is independent of Mg2+ influx. Another possible reason is that it needs another Mg2+ transporter like SLC41A2 to rescue the deficiency . Further studies are required to investigate these issues.
Altogether, our findings suggest an important role of TRPM7 and its potential mechanisms in astrocyte proliferation and migration, which might aid in the further understanding of astrocyte biology. Our current studies, however, have limitations including: 1) The lack of in vivo experimental evidence; 2) No highly selective TRPM7 inhibitors available; 3) Did not examine the potential role of TRPM7 in the pathological processes such as ischemia and oxidative stress.
S1 Fig. Primary cortical astrocytes were isolated from mouse embryonic cortex, and cultured on coverslip pre-coated with poly-L-ornithine.
Cells were incubated with GFAP primary antibody at 4°C overnight, and then incubated with FITC-conjugated second antibody at room temperature for 1h. Phase contrast image indicates total cells. Fluorescence image indicates GFAP positive astrocytes (green). No (-) primary antibody image indicates negative control.
Conceived and designed the experiments: ZZ XCF ZGX. Performed the experiments: ZZ XCF TL. Analyzed the data: ZZ XCF TL HS KI. Wrote the paper: ZZ TL LZ ZGX.
- 1. Montgomery DL. Astrocytes: Form, functions, and roles in disease. Vet Pathol. 1994; 31: 145–67. pmid:8203078
- 2. Sofroniew MV, Vinters HV. Astrocytes: Biology and pathology. Acta Neuropathol. 2010; 119: 7–35. pmid:20012068
- 3. Dong Y, Benveniste EN. Immune function of astrocytes. Glia. 2001; 36: 180–90. pmid:11596126
- 4. Colangelo AM, Alberghina L, Papa M. Astrogliosis as a therapeutic target for neurodegenerative diseases. Neurosci Lett. 2014.
- 5. Shibasaki K, Ishizaki Y, Mandadi S. Astrocytes express functional trpv2 ion channels. Biochem Biophys Res Commun. 2013; 441: 327–32. pmid:24161738
- 6. Malarkey EB, Ni Y, Parpura V. Ca2+ entry through trpc1 channels contributes to intracellular ca2+ dynamics and consequent glutamate release from rat astrocytes. Glia. 2008; 56: 821–35. pmid:18338793
- 7. Song X, Zhao Y, Narcisse L, Duffy H, Kress Y, Lee S, et al. Canonical transient receptor potential channel 4 (trpc4) co-localizes with the scaffolding protein zo-1 in human fetal astrocytes in culture. Glia. 2005; 49: 418–29. pmid:15540229
- 8. Butenko O, Dzamba D, Benesova J, Honsa P, Benfenati V, Rusnakova V, et al. The increased activity of trpv4 channel in the astrocytes of the adult rat hippocampus after cerebral hypoxia/ischemia. PLoS One. 2012; 7: e39959. pmid:22761937
- 9. Scimemi A. A trp among the astrocytes. J Physiol. 2013; 591: 9–15. pmid:23045334
- 10. Shigetomi E, Tong X, Kwan KY, Corey DP, Khakh BS. Trpa1 channels regulate astrocyte resting calcium and inhibitory synapse efficacy through gat-3. Nat Neurosci. 2012; 15: 70–80. pmid:22158513
- 11. Shirakawa H, Sakimoto S, Nakao K, Sugishita A, Konno M, Iida S, et al. Transient receptor potential canonical 3 (trpc3) mediates thrombin-induced astrocyte activation and upregulates its own expression in cortical astrocytes. J Neurosci. 2010; 30: 13116–29. pmid:20881130
- 12. Clapham DE, Runnels LW, Strubing C. The trp ion channel family. Nat Rev Neurosci. 2001; 2: 387–96. pmid:11389472
- 13. Runnels LW, Yue L, Clapham DE. Trp-plik, a bifunctional protein with kinase and ion channel activities. Science. 2001; 291: 1043–7. pmid:11161216
- 14. Nadler MJ, Hermosura MC, Inabe K, Perraud AL, Zhu Q, Stokes AJ, et al. Ltrpc7 is a mg.Atp-regulated divalent cation channel required for cell viability. Nature. 2001; 411: 590–5. pmid:11385574
- 15. Bates-Withers C, Sah R, Clapham DE. Trpm7, the mg(2+) inhibited channel and kinase. Adv Exp Med Biol. 2011; 704: 173–83. pmid:21290295
- 16. Leng T, Shi Y, Xiong ZG, Sun D. Proton-sensitive cation channels and ion exchangers in ischemic brain injury: New therapeutic targets for stroke? Prog Neurobiol. 2014.
- 17. Runnels LW. Trpm6 and trpm7: A mul-trp-plik-cation of channel functions. Curr Pharm Biotechnol. 2011; 12: 42–53. pmid:20932259
- 18. Aarts M, Iihara K, Wei WL, Xiong ZG, Arundine M, Cerwinski W, et al. A key role for trpm7 channels in anoxic neuronal death. Cell. 2003; 115: 863–77. pmid:14697204
- 19. Aarts MM, Tymianski M. Trpm7 and ischemic cns injury. Neuroscientist. 2005; 11: 116–23. pmid:15746380
- 20. Fonfria E, Murdock PR, Cusdin FS, Benham CD, Kelsell RE, McNulty S. Tissue distribution profiles of the human trpm cation channel family. J Recept Signal Transduct Res. 2006; 26: 159–78. pmid:16777713
- 21. Kunert-Keil C, Bisping F, Kruger J, Brinkmeier H. Tissue-specific expression of trp channel genes in the mouse and its variation in three different mouse strains. BMC Genomics. 2006; 7: 159. pmid:16787531
- 22. Sun HS, Jackson MF, Martin LJ, Jansen K, Teves L, Cui H, et al. Suppression of hippocampal trpm7 protein prevents delayed neuronal death in brain ischemia. Nat Neurosci. 2009; 12: 1300–7. pmid:19734892
- 23. Hermosura MC, Garruto RM. Trpm7 and trpm2-candidate susceptibility genes for western pacific als and pd? Biochim Biophys Acta. 2007; 1772: 822–35. pmid:17395433
- 24. Landman N, Jeong SY, Shin SY, Voronov SV, Serban G, Kang MS, et al. Presenilin mutations linked to familial alzheimer's disease cause an imbalance in phosphatidylinositol 4,5-bisphosphate metabolism. Proc Natl Acad Sci U S A. 2006; 103: 19524–9. pmid:17158800
- 25. Jiang X, Newell EW, Schlichter LC. Regulation of a trpm7-like current in rat brain microglia. J Biol Chem. 2003; 278: 42867–76. pmid:12904301
- 26. Siddiqui T, Lively S, Ferreira R, Wong R, Schlichter LC. Expression and contributions of trpm7 and kca2.3/sk3 channels to the increased migration and invasion of microglia in anti-inflammatory activation states. PLoS One. 2014; 9: e106087. pmid:25148577
- 27. Su LT, Chen HC, Gonzalez-Pagan O, Overton JD, Xie J, Yue L, et al. Trpm7 activates m-calpain by stress-dependent stimulation of p38 mapk and c-jun n-terminal kinase. J Mol Biol. 2010; 396: 858–69. pmid:20070945
- 28. Inoue K, Xiong ZG. Silencing trpm7 promotes growth/proliferation and nitric oxide production of vascular endothelial cells via the erk pathway. Cardiovasc Res. 2009; 83: 547–57. pmid:19454490
- 29. Sahni J, Scharenberg AM. Trpm7 ion channels are required for sustained phosphoinositide 3-kinase signaling in lymphocytes. Cell Metab. 2008; 8: 84–93. pmid:18590694
- 30. Schildge S, Bohrer C, Beck K, Schachtrup C. Isolation and culture of mouse cortical astrocytes. J Vis Exp. 2013.
- 31. Inoue K, Branigan D, Xiong ZG. Zinc-induced neurotoxicity mediated by transient receptor potential melastatin 7 channels. J Biol Chem. 2010; 285: 7430–9. pmid:20048154
- 32. Zhang Z, Wang M, Fan XH, Chen JH, Guan YY, Tang YB. Upregulation of trpm7 channels by angiotensin ii triggers phenotypic switching of vascular smooth muscle cells of ascending aorta. Circ Res. 2012; 111: 1137–46. pmid:22896586
- 33. Leng TD, Lin J, Sun HW, Zeng Z, O'Bryant Z, Inoue K, et al. Local anesthetic lidocaine inhibits trpm7 current and trpm7-mediated zinc toxicity. CNS Neurosci Ther. 2014.
- 34. Jiang J, Li MH, Inoue K, Chu XP, Seeds J, Xiong ZG. Transient receptor potential melastatin 7-like current in human head and neck carcinoma cells: Role in cell proliferation. Cancer Res. 2007; 67: 10929–38. pmid:18006838
- 35. Zhang L, Yu H, Sun Y, Lin X, Chen B, Tan C, et al. Protective effects of salidroside on hydrogen peroxide-induced apoptosis in sh-sy5y human neuroblastoma cells. Eur J Pharmacol. 2007; 564: 18–25. pmid:17349619
- 36. Barreto GE, Sun X, Xu L, Giffard RG. Astrocyte proliferation following stroke in the mouse depends on distance from the infarct. PLoS One. 2011; 6: e27881. pmid:22132159
- 37. Hamby ME, Sofroniew MV. Reactive astrocytes as therapeutic targets for cns disorders. Neurotherapeutics. 2010; 7: 494–506. pmid:20880511
- 38. Schmitz C, Perraud AL, Johnson CO, Inabe K, Smith MK, Penner R, et al. Regulation of vertebrate cellular mg2+ homeostasis by trpm7. Cell. 2003; 114: 191–200. pmid:12887921
- 39. Su LT, Liu W, Chen HC, Gonzalez-Pagan O, Habas R, Runnels LW. Trpm7 regulates polarized cell movements. Biochem J. 2011; 434: 513–21. pmid:21208190
- 40. Nunez-Villena F, Becerra A, Echeverria C, Briceno N, Porras O, Armisen R, et al. Increased expression of the transient receptor potential melastatin 7 channel is critically involved in lipopolysaccharide-induced reactive oxygen species-mediated neuronal death. Antioxid Redox Signal. 2011; 15: 2425–38. pmid:21539414
- 41. Schilling T, Miralles F, Eder C. Trpm7 channels regulate proliferation and polarisation of macrophages. J Cell Sci. 2014.
- 42. Liu H, Li J, Huang Y, Huang C. Inhibition of transient receptor potential melastain 7 channel increases hscs apoptosis induced by trail. Life Sci. 2012; 90: 612–8. pmid:22406504
- 43. Sun Y, Sukumaran P, Varma A, Derry S, Sahmoun AE, Singh BB. Cholesterol-induced activation of trpm7 regulates cell proliferation, migration, and viability of human prostate cells. Biochim Biophys Acta. 2014; 1843: 1839–50. pmid:24769209
- 44. Yu M, Huang C, Huang Y, Wu X, Li X, Li J. Inhibition of trpm7 channels prevents proliferation and differentiation of human lung fibroblasts. Inflamm Res. 2013; 62: 961–70. pmid:23934071
- 45. Chen KH, Xu XH, Liu Y, Hu Y, Jin MW, Li GR. Trpm7 channels regulate proliferation and adipogenesis in 3t3-l1 preadipocytes. J Cell Physiol. 2014; 229: 60–7. pmid:23765921
- 46. Baldoli E, Castiglioni S, Maier JA. Regulation and function of trpm7 in human endothelial cells: Trpm7 as a potential novel regulator of endothelial function. PLoS One. 2013; 8: e59891. pmid:23533657
- 47. Sun H, Leng T, Zeng Z, Gao X, Inoue K, Xiong ZG. Role of trpm7 channels in hyperglycemia-mediated injury of vascular endothelial cells. PLoS One. 2013; 8: e79540. pmid:24223965
- 48. Su LT, Agapito MA, Li M, Simonson WT, Huttenlocher A, Habas R, et al. Trpm7 regulates cell adhesion by controlling the calcium-dependent protease calpain. J Biol Chem. 2006; 281: 11260–70. pmid:16436382
- 49. Dorovkov MV, Ryazanov AG. Phosphorylation of annexin i by trpm7 channel-kinase. J Biol Chem. 2004; 279: 50643–6. pmid:15485879
- 50. Clark K, Middelbeek J, Dorovkov MV, Figdor CG, Ryazanov AG, Lasonder E, et al. The alpha-kinases trpm6 and trpm7, but not eef-2 kinase, phosphorylate the assembly domain of myosin iia, iib and iic. FEBS Lett. 2008; 582: 2993–7. pmid:18675813
- 51. Fang L, Zhan S, Huang C, Cheng X, Lv X, Si H, et al. Trpm7 channel regulates pdgf-bb-induced proliferation of hepatic stellate cells via pi3k and erk pathways. Toxicol Appl Pharmacol. 2013; 272: 713–25. pmid:23958495
- 52. Cheng P, Alberts I, Li X. The role of erk1/2 in the regulation of proliferation and differentiation of astrocytes in developing brain. Int J Dev Neurosci. 2013; 31: 783–9. pmid:24113259
- 53. Clark MA, Nguyen C, Tran H. Angiotensin iii induces c-jun n-terminal kinase leading to proliferation of rat astrocytes. Neurochem Res. 2012; 37: 1475–81. pmid:22399333
- 54. Clark MA, Guillaume G, Pierre-Louis HC. Angiotensin ii induces proliferation of cultured rat astrocytes through c-jun n-terminal kinase. Brain Res Bull. 2008; 75: 101–6. pmid:18158102
- 55. Liu M, Inoue K, Leng T, Guo S, Xiong ZG. Trpm7 channels regulate glioma stem cell through stat3 and notch signaling pathways. Cell Signal. 2014; 26: 2773–2781. pmid:25192910
- 56. Baldoli E, Maier JA. Silencing trpm7 mimics the effects of magnesium deficiency in human microvascular endothelial cells. Angiogenesis. 2012; 15: 47–57. pmid:22183257
- 57. Jin J, Desai BN, Navarro B, Donovan A, Andrews NC, Clapham DE. Deletion of trpm7 disrupts embryonic development and thymopoiesis without altering mg2+ homeostasis. Science. 2008; 322: 756–60. pmid:18974357
- 58. Akita T, Okada Y. Regulation of bradykinin-induced activation of volume-sensitive outwardly rectifying anion channels by ca2+ nanodomains in mouse astrocytes. J Physiol. 2011; 589: 3909–27. pmid:21690189
- 59. Babu AN, Cheng TP, Zhang A, Altura BT, Altura BM. Low concentrations of ethanol deplete type-2 astrocytes of intracellular free magnesium. Brain Res Bull. 1999; 50: 59–62. pmid:10507473
- 60. Li W, Yu J, Liu Y, Huang X, Abumaria N, Zhu Y, et al. Elevation of brain magnesium prevents synaptic loss and reverses cognitive deficits in alzheimer inverted question marks disease mouse model. Mol Brain. 2014; 7: 65. pmid:25213836
- 61. Ghabriel MN, Thomas A, Vink R. Magnesium restores altered aquaporin-4 immunoreactivity following traumatic brain injury to a pre-injury state. Acta Neurochir Suppl. 2006; 96: 402–6. pmid:16671494
- 62. Yee NS, Zhou W, Liang IC. Transient receptor potential ion channel trpm7 regulates exocrine pancreatic epithelial proliferation by mg2+-sensitive socs3a signaling in development and cancer. Dis Model Mech. 2011; 4: 240–54. pmid:21183474